CN101904840A - 治疗哺乳动物包括人2型糖尿病的药物组合物 - Google Patents
治疗哺乳动物包括人2型糖尿病的药物组合物 Download PDFInfo
- Publication number
- CN101904840A CN101904840A CN2009101406134A CN200910140613A CN101904840A CN 101904840 A CN101904840 A CN 101904840A CN 2009101406134 A CN2009101406134 A CN 2009101406134A CN 200910140613 A CN200910140613 A CN 200910140613A CN 101904840 A CN101904840 A CN 101904840A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- acceptable salt
- metformin
- described pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
血浆葡萄糖 | 血红蛋白 | |
对照组 | 356±31 | 5.9±0.5 |
化合物A对甲苯磺酸盐 | 224±52* | 5.9±0.3 |
二甲双胍盐酸盐 | 327±45 | 6.2±0.6 |
LAF-237 | 284±31 | 6.1±0.4 |
HAF-237+二甲双胍盐酸盐 | 175±13* | 4.7±0.5* |
化合物A对甲苯磺酸盐+二甲双胍盐酸盐 | 125±21* | 4.3±0.4* |
Claims (9)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009101406134A CN101904840B (zh) | 2009-06-08 | 2009-06-08 | 治疗哺乳动物包括人2型糖尿病的药物组合物 |
PCT/CN2010/072715 WO2010142183A1 (zh) | 2009-06-08 | 2010-05-13 | 治疗哺乳动物包括人2型糖尿病的药物组合物 |
HK11101957.6A HK1147700A1 (en) | 2009-06-08 | 2011-02-28 | Pharmaceutical composition for the treatment of type 2 diabetes in mammals including man |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009101406134A CN101904840B (zh) | 2009-06-08 | 2009-06-08 | 治疗哺乳动物包括人2型糖尿病的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101904840A true CN101904840A (zh) | 2010-12-08 |
CN101904840B CN101904840B (zh) | 2012-02-08 |
Family
ID=43260529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009101406134A Active CN101904840B (zh) | 2009-06-08 | 2009-06-08 | 治疗哺乳动物包括人2型糖尿病的药物组合物 |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN101904840B (zh) |
HK (1) | HK1147700A1 (zh) |
WO (1) | WO2010142183A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104030967A (zh) * | 2013-03-05 | 2014-09-10 | 上海源力生物技术有限公司 | 一种dpp-iv抑制剂的中间体、其制备方法和通过其制备dpp-iv抑制剂的方法 |
CN114401724A (zh) * | 2019-09-27 | 2022-04-26 | 深圳信立泰药业股份有限公司 | 一种降糖药物组合物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101045039A (zh) * | 2001-09-28 | 2007-10-03 | 太阳医药工业有限公司 | 糖尿病治疗剂型 |
CN101365432B (zh) * | 2005-12-16 | 2011-06-22 | 默沙东公司 | 二肽基肽酶-4抑制剂与二甲双胍的组合的药物组合物 |
CN101230059B (zh) * | 2007-01-23 | 2011-08-17 | 上海恒瑞医药有限公司 | 双环氮杂烷类衍生物、其制备方法及其在医药上的用途 |
-
2009
- 2009-06-08 CN CN2009101406134A patent/CN101904840B/zh active Active
-
2010
- 2010-05-13 WO PCT/CN2010/072715 patent/WO2010142183A1/zh active Application Filing
-
2011
- 2011-02-28 HK HK11101957.6A patent/HK1147700A1/xx not_active IP Right Cessation
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104030967A (zh) * | 2013-03-05 | 2014-09-10 | 上海源力生物技术有限公司 | 一种dpp-iv抑制剂的中间体、其制备方法和通过其制备dpp-iv抑制剂的方法 |
CN104030967B (zh) * | 2013-03-05 | 2018-01-02 | 连云港恒运药业有限公司 | 一种dpp‑iv抑制剂的中间体、其制备方法和通过其制备dpp‑iv抑制剂的方法 |
CN114401724A (zh) * | 2019-09-27 | 2022-04-26 | 深圳信立泰药业股份有限公司 | 一种降糖药物组合物 |
CN114401724B (zh) * | 2019-09-27 | 2024-05-24 | 深圳信立泰药业股份有限公司 | 一种降糖药物组合物 |
Also Published As
Publication number | Publication date |
---|---|
HK1147700A1 (en) | 2011-08-19 |
CN101904840B (zh) | 2012-02-08 |
WO2010142183A1 (zh) | 2010-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101365432B (zh) | 二肽基肽酶-4抑制剂与二甲双胍的组合的药物组合物 | |
US20120059011A1 (en) | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone | |
CN106924208A (zh) | 一种复方达格列净二甲双胍缓释片及其制备方法 | |
JP2013508370A (ja) | ジペプチジルペプチダーゼ−4阻害剤とピオグリタゾンとの組み合わせの医薬組成物 | |
CN107432869A (zh) | 包含盐酸二甲双胍和恩格列净的双层片及其制备方法 | |
CN101904840B (zh) | 治疗哺乳动物包括人2型糖尿病的药物组合物 | |
CN103251593B (zh) | 瑞格列奈二甲双胍组合物 | |
CN101919851B (zh) | 治疗哺乳动物包括人2型糖尿病的药物组合物 | |
CN101849944A (zh) | 治疗2型糖尿病的药物组合物 | |
JP5713990B2 (ja) | 2型糖尿病治療用の医薬組成物 | |
CN101961336B (zh) | 治疗哺乳动物包括人2型糖尿病的药物组合物 | |
CN103007286B (zh) | 一种托伐普坦的固体药物组合物 | |
CN100455288C (zh) | 一种盐酸雷诺嗪制剂配方 | |
TWI484955B (zh) | 治療包括人類之哺乳動物中第2型糖尿病的醫藥組成物 | |
TWI462925B (zh) | 治療2型糖尿病的藥物組合物 | |
TWI494313B (zh) | 治療包括人類之哺乳動物中第2型糖尿病的醫藥組成物 | |
TW201219384A (en) | Pharmaceutical composition for the treatment of type 2 diabetes in mammals including human beings |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1147700 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1147700 Country of ref document: HK |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180427 Address after: 222047 No. 7 Kunlun Shan Road, Lianyungang economic and Technological Development Zone, Jiangsu Co-patentee after: Shanghai Sheng Di Medicine Co., Ltd. Patentee after: Hengrui Medicine Co., Ltd., Jiangsu Prov. Address before: 222002 No. 145 Renmin East Road, Sinpo District, Lianyungang, Jiangsu Patentee before: Hengrui Medicine Co., Ltd., Jiangsu Prov. |